NDLI: Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial

Content Provider	Springer Nature Link
Author	Pujol, Pascal Lasset, Christine Berthet, Pascaline Dugast, Catherine Delaloge, Suzette Fricker, Jean Pierre Tennevet, Isabelle Chabbert Buffet, Nathalie This, Pascale Baudry, Karen Lemonnier, Jerome Roca, Lise Mijonnet, Sylvie Gesta, Paul Chiesa, Jean Dreyfus, Helene Vennin, Philippe Delnatte, Capucine Bign, Yves Jean Lortholary, Alain Prieur, Fabienne Gladieff, Laurence Lesur, Anne Clough, Krishna B. gues, Catherine Martin, Anne Laure
Copyright Year	2011
Abstract	Women with germline BRCA1 or BRCA2 (BRCA1/2) mutations are considered as an extreme risk population for developing breast cancer. Prophylactic mastectomy provides a valid option to reduce such risk, impacting however, the quality of life. Medical prevention by aromatase inhibitor that has also recently shown to have preventive effect may thus be considered as an alternative. LIBER is an ongoing double-blind, randomized phase III trial to evaluate the efficacy of 5-year letrozole versus placebo to decrease breast cancer incidence in post-menopausal BRCA1/2 mutation carriers (NCT00673335). We present data on the uptake of this trial. We compared characteristics of women in the LIBER trial (n = 113) to those of women enrolled in the prospective ongoing national GENEPSO cohort (n = 1,505). Uptake was evaluated through a survey sent to all active centres, with responses obtained from 17 to the 20 (85%) centres. According to the characteristics of the women enrolled in the GENEPSO cohort and the survey, approximately one-third of BRCA1/2 mutation carriers were eligible for the trial. Five hundred and thirty-four women eligible from chart review have been informed by mail about the prevention trial and were invited to an oral information by participating centres. Forty-four percentage of them came to the dedicated medical visit. Uptake of drug prevention trial was 32% among women informed orally and 15% of all the eligible women. The main reasons of refusal were: potential side effects, probability to receive the placebo and lack of support from their physicians. Additionally, we noticed that prior prophylactic oophorectomy and previous unilateral breast cancer were more frequent in women enrolled in the LIBER trial than in the French cohort (93% vs. 60% and 50% vs. 39%, respectively). Based on an overall 15% uptake among all eligible subjects, greater and wider information of the trial should be offered to women with BRCA1/2 mutation to improve recruitment. Women with previous unilateral breast cancer or prior prophylactic oophorectomy are more likely to enter a medical prevention trial.
Starting Page	77
Ending Page	84
Page Count	8
File Format	PDF
ISSN	13899600
Journal	Familial Cancer
Volume Number	11
Issue Number	1
e-ISSN	15737292
Language	English
Publisher	Springer Netherlands
Publisher Date	2011-11-11
Publisher Place	Dordrecht
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Letrozole Chemoprevention Uptake Breast cancer BRCA1 BRCA2 Cancer Research Biomedicine general Human Genetics Epidemiology
Content Type	Text
Resource Type	Article
Subject	Genetics Cancer Research Genetics (clinical) Oncology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Cuba

BRCA1 and BRCA2 germline mutations in 85 Iranian breast cancer patients

Low prevalence of BRCA1 and BRCA2 mutations in the sporadic breast cancer of Spanish population

Risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a 30-year semi-prospective analysis

Non-cancer endpoints in BRCA1/2 carriers after risk-reducing salpingo-oophorectomy

Identification of a Danish breast/ovarian cancer family double heterozygote for BRCA1 and BRCA2 mutations

High frequency of BRCA1 founder mutations in Polish women with nonfamilial breast cancer

BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study

Predicting BRCA1 and BRCA2 gene mutation carriers: comparison of PENN II model to previous study

Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial

Similar Documents

Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Cuba

BRCA1 and BRCA2 germline mutations in 85 Iranian breast cancer patients

Low prevalence of BRCA1 and BRCA2 mutations in the sporadic breast cancer of Spanish population

Risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a 30-year semi-prospective analysis

Non-cancer endpoints in BRCA1/2 carriers after risk-reducing salpingo-oophorectomy

Identification of a Danish breast/ovarian cancer family double heterozygote for BRCA1 and BRCA2 mutations

High frequency of BRCA1 founder mutations in Polish women with nonfamilial breast cancer

BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study

Predicting BRCA1 and BRCA2 gene mutation carriers: comparison of PENN II model to previous study

Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial